 |
|
New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
James McKenney, PharmD
Arch Intern Med. 2004;164:697-705.
Therapy with niacin (nicotinic acid) is unique in that it improves all lipoprotein abnormalities. It significantly reduces low-density lipoprotein cholesterol, triglyceride, and lipoprotein(a) levels, while increasing high-density lipoprotein cholesterol levels. This makes niacin ideal for treating a wide variety of lipid disorders, including the metabolic syndrome, diabetes mellitus, isolated low high-density lipoprotein cholesterol, and hypertriglyceridemia. Niacin-induced changes in serum lipid levels produce significant improvements in both coronary artery disease and clinical outcomes. Niacin is currently available in 3 formulations (immediate release, extended release, and long acting), which differ significantly with respect to their safety and efficacy profiles. Immediate-release niacin is generally taken 3 times a day and is associated with adverse flushing, gastrointestinal symptoms, and elevations in blood glucose levels. Long-acting niacin can be taken once daily and is associated with significantly reduced flushing, but its metabolism increases the risk of hepatotoxic effects. Extended-release niacin, also given once daily, has an absorption rate intermediate between the other formulations and is associated with fewer flushing and gastrointestinal symptoms without increasing hepatotoxic risk.
From National Clinical Research and Virginia Commonwealth University, Richmond. Dr McKenney has served as a consultant for AstraZeneca and Pfizer; received speaking honoraria from AstraZeneca, Kos Pharmaceuticals, Merck, and Pfizer; and received research grants from AstraZeneca, BMS, GSK, Kos Pharmaceuticals, Merck, Pfizer, Sanyko, and Schering Plough.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Niacin-induced "Flush" Involves Release of Prostaglandin D2 from Mast Cells and Serotonin from Platelets: Evidence from Human Cells in Vitro and an Animal Model
Papaliodis et al.
J. Pharmacol. Exp. Ther. 2008;327:665-672.
ABSTRACT
| FULL TEXT
Lipoprotein Metabolism and Lipid Management in Chronic Kidney Disease
Kwan et al.
J. Am. Soc. Nephrol. 2007;18:1246-1261.
FULL TEXT
Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium
Rink et al.
Physiol. Genomics 2006;27:370-379.
ABSTRACT
| FULL TEXT
Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products.
Poon et al.
Am J Health Syst Pharm 2006;63:2128-2134.
ABSTRACT
| FULL TEXT
HDL and the progression of atherosclerosis: new insights
Sirtori
Eur Heart J Suppl 2006;8:F4-F9.
ABSTRACT
| FULL TEXT
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Kontush and Chapman
Pharmacol. Rev. 2006;58:342-374.
ABSTRACT
| FULL TEXT
Adherence and Persistence with Single-Dosage Form Extended-Release Niacin/Lovastatin Compared with Statins Alone or in Combination with Extended-Release Niacin
LaFleur et al.
The Annals of Pharmacotherapy 2006;40:1274-1279.
ABSTRACT
| FULL TEXT
Hypertriglyceridemia.
Pejic and Lee
J Am Board Fam Med 2006;19:310-316.
ABSTRACT
| FULL TEXT
Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
Clark et al.
J. Lipid Res. 2006;47:537-552.
ABSTRACT
| FULL TEXT
The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor
Espinosa-Larranaga et al.
Diabetes and Vascular Disease Research 2005;2:S1-S8.
ABSTRACT
Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus: The Pan-Asian Consensus Panel On Hdl-C
Barter
British Journal of Diabetes & Vascular Disease 2005;5:S1-S15.
ABSTRACT
Stopping Statins
Stone
Circulation 2004;110:2280-2282.
FULL TEXT
|
